[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.]
[L01CA01, vinblastine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.]
[C04AX07, vincamine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincamine.]
[L01CA02, vincristine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vindesine.]
[L03AB11, peginterferon alfa-2a, The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegfilgrastim.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegfilgrastim.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegfilgrastim.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.]
[L01AA01, cyclophosphamide, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L01XX24, pegaspargase, The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.]
[L01CA04, vinorelbine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegfilgrastim.]
[L01CE01, topotecan, The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.]
[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.]
[L01CA01, vinblastine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.]
[C04AX07, vincamine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincamine.]
[L01CA02, vincristine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vindesine.]
[L03AB11, peginterferon alfa-2a, The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegfilgrastim.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegfilgrastim.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegfilgrastim.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.]
[L01AA01, cyclophosphamide, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L01XX24, pegaspargase, The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.]
[L01CA04, vinorelbine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegfilgrastim.]
[L01CE01, topotecan, The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.]
[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.]
[L01CA01, vinblastine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.]
[C04AX07, vincamine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincamine.]
[L01CA02, vincristine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vindesine.]
[L03AB11, peginterferon alfa-2a, The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegfilgrastim.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegfilgrastim.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegfilgrastim.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.]
[L01AA01, cyclophosphamide, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L01XX24, pegaspargase, The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.]
[L01CA04, vinorelbine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegfilgrastim.]
[L01CE01, topotecan, The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.]
[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.]
[L01CA01, vinblastine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.]
[C04AX07, vincamine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincamine.]
[L01CA02, vincristine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vindesine.]
[L03AB11, peginterferon alfa-2a, The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegfilgrastim.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegfilgrastim.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegfilgrastim.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.]
[L01AA01, cyclophosphamide, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L01XX24, pegaspargase, The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.]
[L01CA04, vinorelbine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegfilgrastim.]
[L01CE01, topotecan, The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.]
[M04AX02, pegloticase, The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.]
[L01CA01, vinblastine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.]
[C04AX07, vincamine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincamine.]
[L01CA02, vincristine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vindesine.]
[L03AB11, peginterferon alfa-2a, The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.]
[B03XA04, peginesatide, The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.]
[L03AA14, lipegfilgrastim, The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegfilgrastim.]
[L03AB13, peginterferon beta-1a, The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegfilgrastim.]
[A16AB19, pegvaliase, The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegfilgrastim.]
[L03AX21, elapegademase, The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.]
[L03AB10, peginterferon alfa-2b, The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.]
[L01AA01, cyclophosphamide, The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.]
[L01XX24, pegaspargase, The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.]
[L01CA04, vinorelbine, The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.]
[S01LA03, pegaptanib, The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegfilgrastim.]
[L01CE01, topotecan, The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.]
[L03AX04, pegademase bovine, The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.]
[L04AB05, certolizumab pegol, The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.]
[C05BB02, polidocanol, The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.]
